Azurity Pharmaceuticals – XIFYRM™: Minimizing Risk, Maximizing Clarity: The Story Behind XIFYRM™

On June 5, 2025, the FDA granted approval for XIFYRM™, an intravenous meloxicam injection developed by Azurity Pharmaceuticals for the management of moderate to severe pain in adults. As a fast-acting, non-opioid treatment option, XIFYRM™ addresses a critical need in hospital and acute care settings, where effective and opioid-sparing pain management is a growing priority.

The pharmaceutical brand name XIFYRM™, created by Want Branding, underwent a comprehensive drug name risk assessment conducted by Brandsymbol’s Regulatory division. This work was part of a dual-track initiative supporting Azurity’s broader product portfolio and regulatory strategy.

To ensure regulatory readiness, Azurity Pharmaceuticals partnered with Brandsymbol for an objective, third-party risk assessment of the proposed name.

The name passed with comments, indicating no significant overlap with existing drug names while highlighting a few areas for internal legal follow-up. This assessment empowered Azurity to proceed confidently, balancing regulatory compliance with creative intent.

Ultimately, the FDA approval of XIFYRM™ reinforces Brandsymbol’s role as a trusted partner in pharmaceutical branding, helping clients navigate the complexities of drug name development and regulatory screening with clarity, strategy, and precision.

Learn how Brandsymbol’s regulatory tools and expertise helped clear the path for XIFYRM™.

FDA Approves XIFYRM™: Azurity’s New IV Meloxicam Option for Acute Pain in Adults